Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001532 · ClinicalTrials.gov registry record
Role of Genetic Factors in the Development of Lung Disease
A clinical trial of Asthma and Cystic Fibrosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 3,500
- Enrollment target
- 2
- Study locations
NCT00001532: Recruiting study of Asthma and Cystic Fibrosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00001532 is a study of Asthma and Cystic Fibrosis that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 3,500 participants, above the 1,554-participant average among 374 other Asthma trials with a reported enrollment target (125% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001532, a study of Asthma and Cystic Fibrosis, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 3,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT scan for the 150 subjects enrolled in the sub-study to assess the variation between the two techniques. Specifically, the quantitative computer aided detection of lung CT abnormalities from LAM can be compared to assess whether low radiation dose CT exams is an alternative to conventional CT to monitor disease status. This optional sub-study will be offered to up to 100 adult subjects with lung disease and up to 50 children age 9 and older with CF. Children will not be enrolled in the optional CT sub-study unless they have had a standard CT scan for medical purposes to use in comparison. One additional low dose radiation CT scan of the chest may be done as part of this sub-study when these subjects have their next annual CT scan.
Primary Outcome
distribution of genetic variants of nitric oxide synthases and other candidate genes involved in pulmonary function
Conditions Studied
Study Locations (2)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 1996-09-13 |
What NCT00001532 shows while recruiting
NCT00001532 is an observational study that tracks outcomes without assigning an intervention. Its 3,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,554-participant average among 374 other Asthma trials with a reported enrollment target (125% higher).
The record links to 5 conditions, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT00001532 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001532 about?
NCT00001532 is a clinical study titled "Role of Genetic Factors in the Development of Lung Disease". This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible fo...
What is the current status of trial NCT00001532?
This trial is currently recruiting. The enrollment target is 3,500 participants. The study started on 1996-09-13.
What conditions does trial NCT00001532 study?
This clinical trial studies the following conditions: Asthma, Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Pulmonary Sarcoidosis.
Who is sponsoring clinical trial NCT00001532?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001532 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001532's enrollment target sits among peer trials
3,500 14th of 374 higher than 361 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI